Back to Journals » Clinical Optometry » Volume 11

Monitoring and Management of the Patient with Stargardt Disease

Authors Cicinelli MV, Battista M, Starace V, Battaglia Parodi M, Bandello F

Received 24 September 2019

Accepted for publication 16 November 2019

Published 28 November 2019 Volume 2019:11 Pages 151—165


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Mr Simon Berry

Maria Vittoria Cicinelli, Marco Battista, Vincenzo Starace, Maurizio Battaglia Parodi, Francesco Bandello

Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy

Correspondence: Maria Vittoria Cicinelli
Department of Ophthalmology, San Raffaele Vita-Salute University, Via Olgettina, 60, Milano 20132, Italy
Tel +39 02 26432648
Fax +39 02 26483643

Abstract: Stargardt disease (STGD1) represents one of the major common causes of inherited irreversible visual loss. Due to its high phenotypic and genotypic heterogeneity, STGD1 is a complex disease to understand. Non-invasive imaging, biochemical, and genetic advances have led to substantial improvements in unveiling the disease processes and novel promising therapeutic landscapes have been proposed. This review recapitulates the modalities for monitoring patients with STGD1 and the therapeutic options currently under investigation for the different stages of the disease.

Keywords: Stargardt disease, inherited retinal dystrophy, multimodal imaging, optical coherence tomography, gene therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]